Zenas BioPharma, Inc. $ZBIO Stock Holdings Raised by UBS Group AG

UBS Group AG raised its stake in Zenas BioPharma, Inc. (NASDAQ:ZBIO) by 95.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 69,495 shares of the company’s stock after purchasing an additional 34,003 shares during the period. UBS Group AG owned 0.13% of Zenas BioPharma worth $2,523,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Quarry LP increased its position in shares of Zenas BioPharma by 34.5% in the 3rd quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after purchasing an additional 291 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in shares of Zenas BioPharma in the 3rd quarter worth about $30,000. GF Fund Management CO. LTD. bought a new stake in shares of Zenas BioPharma in the 4th quarter worth about $38,000. BNP Paribas Financial Markets increased its position in shares of Zenas BioPharma by 120.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock worth $70,000 after purchasing an additional 1,716 shares during the last quarter. Finally, CWM LLC increased its position in shares of Zenas BioPharma by 48.3% in the 4th quarter. CWM LLC now owns 2,178 shares of the company’s stock worth $79,000 after purchasing an additional 709 shares during the last quarter.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ZBIO. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zenas BioPharma in a research report on Friday, March 27th. Morgan Stanley boosted their price objective on shares of Zenas BioPharma from $21.00 to $22.00 and gave the company an “equal weight” rating in a research report on Thursday, May 14th. Wall Street Zen raised shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Guggenheim boosted their price objective on shares of Zenas BioPharma from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, March 16th. Finally, Citigroup reaffirmed a “buy” rating on shares of Zenas BioPharma in a research report on Thursday, May 14th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $44.29.

Insiders Place Their Bets

In related news, CEO Leon O. Moulder, Jr. purchased 60,000 shares of Zenas BioPharma stock in a transaction dated Monday, May 18th. The stock was bought at an average cost of $16.88 per share, with a total value of $1,012,800.00. Following the purchase, the chief executive officer owned 96,928 shares in the company, valued at approximately $1,636,144.64. The trade was a 162.48% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Fairmount Funds Management Llc purchased 150,000 shares of Zenas BioPharma stock in a transaction dated Tuesday, March 31st. The stock was bought at an average cost of $20.00 per share, with a total value of $3,000,000.00. Following the completion of the purchase, the director owned 2,359,025 shares in the company, valued at approximately $47,180,500. This trade represents a 6.79% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders bought 273,768 shares of company stock worth $5,150,198. Insiders own 22.00% of the company’s stock.

Zenas BioPharma Price Performance

NASDAQ ZBIO opened at $18.73 on Wednesday. Zenas BioPharma, Inc. has a 52 week low of $8.91 and a 52 week high of $44.60. The company has a current ratio of 11.94, a quick ratio of 11.94 and a debt-to-equity ratio of 1.04. The stock has a market cap of $1.18 billion, a price-to-earnings ratio of -2.21 and a beta of -0.61. The company has a 50-day moving average price of $20.29 and a two-hundred day moving average price of $26.15.

Zenas BioPharma (NASDAQ:ZBIO) last posted its earnings results on Wednesday, May 13th. The company reported ($1.46) EPS for the quarter, topping the consensus estimate of ($1.47) by $0.01. During the same quarter in the prior year, the firm posted ($0.80) earnings per share. Analysts forecast that Zenas BioPharma, Inc. will post -4.47 EPS for the current year.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.